(Reuters) - The U.S. Food and Drug Administration has asked the company to include assessment of whether the drug has potential to cause cancer, Somaxon said in a statement.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment